Monaco Asset Management SAM Raises Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Monaco Asset Management SAM lifted its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 372.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,134,444 shares of the company's stock after purchasing an additional 894,444 shares during the quarter. Monaco Asset Management SAM owned about 1.59% of Ventyx Biosciences worth $1,305,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. increased its stake in Ventyx Biosciences by 12.4% in the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock valued at $147,000 after acquiring an additional 7,414 shares during the last quarter. Geode Capital Management LLC boosted its position in Ventyx Biosciences by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company's stock valued at $3,095,000 after buying an additional 21,337 shares during the period. Wells Fargo & Company MN boosted its position in Ventyx Biosciences by 23.3% during the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock valued at $90,000 after buying an additional 7,768 shares during the period. ADAR1 Capital Management LLC boosted its position in Ventyx Biosciences by 27.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 124,530 shares of the company's stock valued at $273,000 after buying an additional 26,575 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Ventyx Biosciences by 99.1% during the fourth quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock valued at $1,368,000 after buying an additional 310,800 shares during the period. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Price Performance

NASDAQ VTYX traded down $0.17 during trading on Friday, hitting $2.63. 546,675 shares of the company's stock traded hands, compared to its average volume of 1,438,776. The stock has a fifty day moving average of $2.44 and a two-hundred day moving average of $1.80. The firm has a market cap of $187.15 million, a P/E ratio of -1.50 and a beta of 0.93. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. As a group, analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.